NEW YORK — An investigational antifibrotic and anti-inflammatory drug could help treat a common complication of diabetes.
Researchers at the University of California-San Diego School of Medicine, the National Institutes of Health and the Mayo Clinic found that pirfenidone potentially could treat diabetic nephropathy, a leading cause of end-stage kidney disease.